Want to see GB:FUM full AI Analyst Report?
Top Page
Futura Medical
(LSE:FUM)
Select Model
Select Model
Rating:44Neutral
Price Target:
0.21 p
▼(-45.38% Downside)
Action:Reiterated
Date:10/02/26
The score is driven primarily by weak financial performance (sharp 2025 revenue decline, return to significant losses, and ongoing cash burn) and bearish technicals (price far below key moving averages with negative MACD). The balance sheet’s zero-debt profile provides some support, but valuation signals are constrained by negative earnings and no dividend data.
Positive Factors
Zero Debt
A zero-debt balance sheet reduces interest obligations and financial leverage, giving Futura greater flexibility while it develops and commercialises MED3000. This structure can help the company withstand operating volatility better than a similarly loss-making business carrying substantial borrowings.
Negative Factors
Sharp Revenue Decline
The steep annual revenue decline demonstrates that commercial performance remains highly volatile and that prior revenue levels have not yet translated into a dependable growth trend. Prolonged weakness would reduce resources available for regulatory work, launches and further product development.
Read all positive and negative factors
Positive Factors
Negative Factors
Zero Debt
A zero-debt balance sheet reduces interest obligations and financial leverage, giving Futura greater flexibility while it develops and commercialises MED3000. This structure can help the company withstand operating volatility better than a similarly loss-making business carrying substantial borrowings.
Read all positive factors
Futura Medical (FUM) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£3.26M
Dividend YieldN/A
Average Volume (3M)10.82M
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth-70.77%
EPS Growth60.39%
CountryUK
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,482,327,800
10 Day Avg. Volume16,492,833
30 Day Avg. Volume10,821,846
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.30
Price to Sales (P/S)2.15
P/FCF Ratio-0.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£5.10M
Futura Medical Business Overview & Revenue Model
Company Description
Futura Medical plc operates as a pharmaceutical firm specializing in the creation and advancement of consumer healthcare products. The company primarily targets the sexual health and pain management sectors. Its leading innovation is MED3000, a to...
How the Company Makes Money
Futura Medical’s business model is primarily based on out-licensing and commercial partnerships rather than building a large in-house salesforce. The company makes money by granting partners the rights to manufacture, market and sell its ED gel (M...
Futura Medical Earnings Call Summary
Earnings Call Date:Sep 30, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Apr 14, 2027
Earnings Call Sentiment Negative
The earnings call reflected significant financial and operational challenges with revenue shortfalls, unexpected market performance, and inventory issues. While there are promising R&D developments, these are long-term. Immediate financial pressures and market challenges dominate the current outlook.Positive Updates
R&D Developments
Futura is advancing two new products: Project Intense and WSD4000. Project Intense aims to enhance sensorial effects for men, with regulatory approval expected by the end of 2025. WSD4000 targets women's sexual response, with significant market potential, though it is expected to launch in the latter half of 2028.
Negative Updates
Revenue Shortfall
Revenues of just over GBP 1 million for H1 2025 fell significantly below expectations, with full-year sales now expected to be between GBP 1.3 million and GBP 1.4 million, far below the initial GBP 5 million projection.
Read all updates
Q2-2025 Updates
Positive
Negative
R&D Developments
Futura is advancing two new products: Project Intense and WSD4000. Project Intense aims to enhance sensorial effects for men, with regulatory approval expected by the end of 2025. WSD4000 targets women's sexual response, with significant market potential, though it is expected to launch in the latter half of 2028.
Read all positive updates
Company Guidance
During the investor presentation call for Futura Medical plc, Interim CEO Alex Duggan provided guidance indicating that the company's full-year 2025 performance is expected to fall significantly below market expectations due to challenges in sustaining consumer uptake and lower-than-anticipated repeat sales. Despite launching in seven countries in H1, the initial strong trials did not translate into continued sales, affecting supply volumes and royalty streams. Angela Hildreth reported a revenue of just over GBP 1 million for the first half of 2025, with a gross profit of GBP 0.7 million, but also highlighted a GBP 0.49 million provision for inventory obsolescence. The company incurred an exceptional charge of GBP 3.6 million due to impairment of U.S. plant and equipment, contributing to a loss after tax of GBP 6.6 million. The adjusted loss after tax was GBP 1.9 million, with cash reserves at GBP 3.69 million at the period's end. Full-year sales for 2025 are now projected to be between GBP 1.3 million and GBP 1.4 million, with cash reserves reduced to GBP 2.7 million by the end of August. The company is actively exploring commercial and financing options to extend its cash runway, which currently runs into January 2026.Futura Medical Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
55
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.32M | 1.70M | 13.93M | 3.10M | 0.00 | 0.00 |
| Gross Profit | 2.44M | 1.24M | 9.57M | 1.77M | -24.73K | -19.81K |
| EBITDA | -152.48K | -5.54M | 1.41M | -6.83M | -6.85M | -5.85M |
| Net Income | -3.67M | -9.07M | 1.29M | -6.51M | -5.85M | -4.96M |
Balance Sheet | ||||||
| Total Assets | 4.15M | 5.22M | 13.59M | 11.82M | 6.47M | 11.80M |
| Cash, Cash Equivalents and Short-Term Investments | 1.24M | 3.40M | 6.60M | 7.71M | 4.03M | 10.37M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.15M | 2.41M | 4.63M | 6.34M | 1.75M | 2.08M |
| Stockholders Equity | 2.01M | 2.81M | 8.96M | 5.48M | 4.72M | 9.72M |
Cash Flow | ||||||
| Free Cash Flow | -4.79M | -5.58M | -1.29M | -935.60K | -6.52M | -4.29M |
| Operating Cash Flow | -4.79M | -5.58M | 438.41K | 570.25K | -5.78M | -3.87M |
| Investing Cash Flow | 0.00 | 38.19K | -1.73M | -1.43M | -740.70K | -419.72K |
| Financing Cash Flow | 2.35M | 2.38M | 170.91K | 4.55M | 169.58K | 13.65M |
Futura Medical Technical Analysis
Neutral
0.39
Price Trends
0.32
Negative
0.43
Negative
0.81
Negative
Market Momentum
-0.03
Negative
41.23
Neutral
47.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:FUM, the sentiment is Neutral. The current price of 0.39 is above the 20-day moving average (MA) of 0.22, above the 50-day MA of 0.32, and below the 200-day MA of 0.81, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 41.23 is Neutral, neither overbought nor oversold. The STOCH value of 47.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:FUM.
Futura Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | £15.55M | -33.33 | -5.25% | ― | 95.16% | 85.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £54.81M | -9.21 | -71.28% | ― | ― | 31.58% | |
47 Neutral | £337.25M | -7.89 | -1293.07% | ― | ― | ― | |
47 Neutral | £6.04M | -1.41 | -77.85% | ― | 11.90% | -2864.29% | |
47 Neutral | £27.37M | 145.00 | 3.75% | ― | ― | ― | |
44 Neutral | £3.26M | -0.35 | -152.41% | ― | -70.77% | 60.39% |
* Healthcare Sector Average
GB:FUM
Futura Medical
0.22
-3.01
-93.19%
GB:AVCT
Avacta Group plc
72.00
1.00
1.41%
GB:OPTI
OptiBiotix Health
5.85
-4.90
-45.58%
GB:SBTX
SkinBioTherapeutics
6.00
-8.88
-59.66%
GB:POLB
Poolbeg Pharma Ltd.
7.18
3.78
111.18%
GB:AREC
Arecor Therapeutics PLC
72.50
-11.50
-13.69%
Futura Medical Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Futura Medical Directors Boost Stakes After Fundraise
Positive
Sep 29, 2026
Futura Medical has disclosed that its directors subscribed for 23,500,000 new ordinary shares following the completion of a recent fundraise. The purchases, all executed on the London Stock Exchange at 0.2p per share, underline senior management&#...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Futura Medical Shareholders Back Major Fundraise to Support Sexual Health Growth Strategy
Positive
Sep 24, 2026
Futura Medical plc, the AIM-listed consumer healthcare group behind Eroxon, specialises in innovative sexual health products for men and women. Its portfolio spans over-the-counter treatments for erectile dysfunction and development-stage gels tar...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Futura Medical Wins Shareholder Backing for Major Fundraise and Share Capital Expansion
Positive
Sep 24, 2026
Futura Medical shareholders have overwhelmingly approved all resolutions at a general meeting, clearing the way for the company’s previously announced placing, subscription and retail offer to proceed. The vote confirms strong investor backi...
Business Operations and StrategyExecutive/Board Changes
Futura Medical Streamlines Board as Non-Executive Director Roy Davis Steps Down
Neutral
Sep 10, 2026
Futura Medical has announced that Non-Executive Director Roy Davis will step down from the board on 20 October 2026, following a review of his wider board commitments and time requirements. The company stressed that his departure is not related to...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Futura Medical Upsizes Oversubscribed Retail Offer, Targets £1.8m Funding
Positive
Sep 7, 2026
Futura Medical has conditionally raised £200,000 from an oversubscribed retail offer on the BookBuild platform, increasing the planned amount from £150,000 through the issue of 100,000,000 new ordinary shares. Together with prior firm an...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Futura Medical Calls General Meeting as Part of Fundraise Process
Positive
Sep 4, 2026
Futura Medical has sent shareholders a circular and notice convening a general meeting as part of its recently announced fundraise, underscoring ongoing efforts to support the commercial rollout of its sexual health portfolio. The meeting will be ...
Business Operations and StrategyM&A TransactionsPrivate Placements and FinancingShareholder Meetings
Futura Medical launches deep-discount retail offer to shore up cash and support sale process
Negative
Sep 3, 2026
Futura Medical has launched a retail offer via the BookBuild platform to existing UK shareholders, seeking to raise up to £150,000 through the issue of up to 75 million new shares at 0.2 pence, a 37.6% discount to the prior closing price. Thi...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Futura Medical Launches Fundraise and Formal Sale Process as Sexual Health Portfolio Grows
Negative
Sep 3, 2026
Futura Medical has launched a multi-part equity fundraising of approximately £1.6 million through firm and conditional placings and a subscription, with an additional retail offer of up to £150,000 at 0.2 pence per share, alongside issui...
Business Operations and StrategyFinancial Disclosures
Futura Medical trims losses, reshapes U.S. strategy as cash runway narrows
Negative
Sep 1, 2026
Futura Medical reported interim results showing revenue of £1.62 million for the first half of 2026, largely driven by a settlement with former U.S. partner Haleon, while underlying royalties from Eroxon remained modest and cash fell to £...
Business Operations and StrategyProduct-Related Announcements
Futura Medical Wins EU and UK Clearance for Eroxon Intense
Positive
Jul 31, 2026
Futura Medical has secured clearance to launch its new Eroxon Intense erectile dysfunction gel across the European Economic Area and the UK, under existing CE and UKCA certifications. The formulation is designed to deliver a faster and stronger se...
Business Operations and StrategyLegal Proceedings
Futura Medical to Appeal Eroxon Patent Revocation as Commercialisation Continues Unaffected
Neutral
Jul 7, 2026
Futura Medical said the European Patent Office’s Opposition Division has issued a written decision confirming revocation of European Patent EP 3934624B1, covering its MED3000 (Eroxon®) erectile dysfunction gel, after a May 8 oral hearin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.